Photocure Study Shows Blue Light Cystoscopy Cost-Neutral in Bladder Cancer Care — Photocure ASA

Event summary

Photocure's study in JU Open Plus found blue light cystoscopy (BLC) cost-neutral compared to white light cystoscopy (WLC) for non-muscle-invasive bladder cancer (NMIBC).
Analysis of U.S. claims data from Optum Research Database showed BLC patients had higher CIS detection rates and more surveillance but no significant cost difference.
Total healthcare costs per patient per month were $2,987.93 for BLC vs. $2,886.16 for WLC (p=0.65), with bladder cancer-specific costs at $1,301.10 vs. $1,246.60 (p=0.75).
Study included 794 BLC patients and 4,764 matched WLC patients from June 2011 to May 2023.

The big picture

Bladder cancer remains a costly disease with high recurrence rates, making accurate diagnosis critical. This study supports BLC as a valuable tool that improves detection without increasing overall costs, aligning with broader trends toward cost-effective diagnostic innovations in oncology. Photocure's ability to demonstrate real-world economic benefits could enhance its commercial positioning and partnership opportunities.

What we're watching

Diagnostic Adoption: Whether BLC's cost-neutral profile will accelerate its adoption in NMIBC management despite higher surveillance utilization.
Long-Term Impact: The pace at which further research confirms BLC's long-term oncologic and economic benefits.
Market Positioning: How Photocure leverages these findings to strengthen its position in bladder cancer diagnostics against competitors.